We examined the antitumor and therapeutic potentials of paricalcitol, an analog of 1,25-dihydroxyvitamin D3 with lower calcemic activity, against uterine fibroids using in vitro and in vivo evaluations in appropriate uterine fibroid cells and animal models. We found that paricalcitol has potential to reduce the proliferation of the immortalized human uterine fibroid cells. For the in vivo study, we generated subcutaneous tumors by injecting the Eker rat-derived uterine leiomyoma cell line (ELT-3) rat uterine fibroid-derived cell line in athymic nude mice supplemented with estrogen pellets. These mice were administered with vehicle versus paricalcitol (300 ng/kg/d) or 1,25-dihydroxyvitamin D3 (500 ng/kg/d) for 4 consecutive weeks, and the data were analyzed. We found that while both paricalcitol and 1,25-dihydroxyvitamin D3 significantly reduced fibroid tumor size, the shrinkage was slightly higher in the paricalcitol-treated group. Together, our results suggest that paricalcitol may be a potential candidate for effective, safe, and noninvasive medical treatment option for uterine fibroids.
FarhiJAshkenaziJFeldbergDDickerDOrvietoRBen RafaelZ. Effect of uterine leiomyomata on the results of in-vitro fertilization treatment. Hum Reprod. 1995;10(10):2576–2578.
5.
Eldar-GevaTMeagherSHealyDLMacLachlanVBrehenySWoodC. Effect of intramural, subserosal, and submucosal uterine fibroids on the outcome of assisted reproductive technology treatment. Fertil Steril. 1998;70(4):687–691.
6.
SurreyESLietzAKSchoolcraftWB. Impact of intramural leiomyomata in patients with a normal endometrial cavity on in vitro fertilization-embryo transfer cycle outcome. Fertil Steril. 2001;75(2):405–410.
7.
HartRKhalafYYeongCTSeedPTaylorABraudeP. A prospective controlled study of the effect of intramural uterine fibroids on the outcome of assisted conception. Hum Reprod. 2001;16(11):2411–2417.
8.
WilcoxLSKooninLMPokrasRStraussLTXiaZPetersonHB. Hysterectomy in the United States, 1988-1990. Obstet Gynecol. 1994;83(4):549–555.
9.
ReinMSBarbieriRLFriedmanAJ. Progesterone: a critical role in the pathogenesis of uterine myomas. Am J Obstet Gynecol. 1995;172(1 pt 1):14–18.
10.
ZittermannASchleithoffSSTenderichGBertholdHKKorferRStehleP. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure?J Am Coll Cardiol. 2003;41(1):105–112.
11.
CardozoERClarkADBanksNKHenneMBStegmannBJSegarsJH. The estimated annual cost of uterine leiomyomata in the United States. Am J Obstet Gynecol. 2012;206(3):211. e211–e219.
12.
ShenSHFennessyFMcDannoldNJoleszFTempanyC. Image-guided thermal therapy of uterine fibroids. Semin Ultrasound CT MR. 2009;30(2):91–104.
13.
Al-HendyASalamaS. Gene therapy and uterine leiomyoma: a review. Hum Reprod Update. 2006;12(4):385–400.
14.
EzzatiMNorianJMSegarsJH. Management of uterine fibroids in the patient pursuing assisted reproductive technologies. Womens Health (Lond Engl). 2009;5(4):413–421.
15.
HassanMHOthmanEEHornungDAl-HendyA. Gene therapy of benign gynecological diseases. Adv Drug Deliv Rev. 2009;61(10):822–835.
16.
ZhangDAl-HendyMRichard-DavisG. Green tea extract inhibits proliferation of uterine leiomyoma cells in vitro and in nude mice. Am J Obstet Gynecol. 2010;202(3):289. e281–289.
17.
HassanMHSalamaSAZhangD. Gene therapy targeting leiomyoma: adenovirus-mediated delivery of dominant-negative estrogen receptor gene shrinks uterine tumors in Eker rat model. Fertil Steril. 2010;93(1):239–250.
18.
NormanAWBouillonR. Vitamin D nutritional policy needs a vision for the future. Exp Biol Med (Maywood). 2010;235(9):1034–1045.
19.
SabryMHalderSKAllahASRoshdyERajaratnamVAl-HendyA. Serum vitamin D3 level inversely correlates with uterine fibroid volume in different ethnic groups: a cross-sectional observational study. Int J Womens Health. 2013;5:93–100.
20.
BairdDDHillMCSchectmanJMHollisBW. Vitamin d and the risk of uterine fibroids. Epidemiology. 2013;24(3):447–453.
21.
PaffoniASomiglianaEViganoP. Vitamin D status in women with uterine leiomyomas. J Clin Endocrinol Metab. 2013;98(8):E1374–E1378.
22.
HalderSKSharanCAl-HendyA. 1,25-dihydroxyvitamin D3 treatment shrinks uterine leiomyoma tumors in the Eker rat model. Biol Reprod. 2012;86(4):116, 1–10.
23.
LiuLCVoorsAAvan VeldhuisenDJ. Vitamin D status and outcomes in heart failure patients. Eur J Heart Fail. 2011;13(6):619–625.
GuytonKZKenslerTWPosnerGH. Cancer chemoprevention using natural vitamin D and synthetic analogs. Annu Rev Pharmacol Toxicol. 2001;41:421–442.
26.
MeemsLMvan der HarstPvan GilstWHde BoerRA. Vitamin D biology in heart failure: molecular mechanisms and systematic review. Curr Drug Targets. 2011;12(1):29–41.
27.
Nesby-O'DellSScanlonKSCogswellME. Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National health and nutrition examination survey, 1988-1994. Am J Clin Nutr. 2002;76(1):187–192.
28.
HolickMF. Too little vitamin D in premenopausal women: why should we care?Am J Clin Nutr. 2002;76(1):3–4.
29.
DownesESikiricaVGilabert-EstellesJ. The burden of uterine fibroids in five European countries. Eur J Obstet Gynecol Reprod Biol. 2010;152(1):96–102.
30.
Al-HendyASalamaSA. Ethnic distribution of estrogen receptor-alpha polymorphism is associated with a higher prevalence of uterine leiomyomas in black Americans. Fertil Steril. 2006;86(3):686–693.
31.
BrandonDDBetheaCLStrawnEY. Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas. Am J Obstet Gynecol. 1993;169(1):78–85.
32.
BrandonDDEricksonTEKeenanEJ. Estrogen receptor gene expression in human uterine leiomyomata. J Clin Endocrinol Metab. 1995;80(6):1876–1881.
33.
ChenTCHolickMF. Vitamin D and prostate cancer prevention and treatment. Trends Endocrinol Metab. 2003;14(9):423–430.
34.
KoliK, Keski-Oja J. 1alpha,25-dihydroxyvitamin D3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells. Cell Growth Differ. 2000;11(4):221–229.
35.
MangelsdorfDJThummelCBeatoMHerrlichPSchutzGUmesonoKBlumbergBKastnerPMarkMChambonP. The nuclear receptor superfamily: the second decade. Cell. 1995, 83(6):835–839.
36.
BouillonRVerstuyfAVerlindenL. Non-hypercalcemic pharmacological aspects of vitamin D analogs. Biochem Pharmacol. 1995;50(5):577–583.
37.
SharanCHalderSKThotaCJaleelTNairSAl-HendyA. Vitamin D inhibits proliferation of human uterine leiomyoma cells via catechol-O-methyltransferase. Fertil Steril. 2011;95(1):247–253.
38.
MillerGJ. Vitamin D and prostate cancer: biologic interactions and clinical potentials. Cancer Metastasis Rev. 1998;17(4):353–360.
39.
MeemsLMCannonMVMahmudH. The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload. J Steroid Biochem Mol Biol. 2012;132(3-5):282–289.
40.
HoweSRGottardisMMEverittJIGoldsworthyTLWolfDCWalkerC. Rodent model of reproductive tract leiomyomata. Establishment and characterization of tumor-derived cell lines. Am J Pathol. 1995;146(6):1568–1579.
41.
Al-HendyAAuerspergN. Applying the herpes simplex virus thymidine kinase/ganciclovir approach to ovarian cancer: an effective in vitro drug-sensitization system. Gynecol Obstet Invest. 1997;43(4):268–275.
42.
HalderSKOsteenKGAl-HendyA. 1,25-dihydroxyvitamin d3 reduces extracellular matrix-associated protein expression in human uterine fibroid cells. Biol Reprod. 2013;89(6):150, 1–13.
43.
MathiasenISLademannUJaattelaM. Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53. Cancer Res. 1999;59(19):4848–4856.
44.
WalkerCLStewartEA. Uterine fibroids: the elephant in the room. Science. 2005;308(5728):1589–1592.
45.
StewartEAFriedmanAJPeckKNowakRA. Relative overexpression of collagen type I and collagen type III messenger ribonucleic acids by uterine leiomyomas during the proliferative phase of the menstrual cycle. J Clin Endocrinol Metab. 1994;79(3):900–906.
46.
DingLXuJLuoXCheginiN. Gonadotropin releasing hormone and transforming growth factor beta activate mitogen-activated protein kinase/extracellularly regulated kinase and differentially regulate fibronectin, type I collagen, and plasminogen activator inhibitor-1 expression in leiomyoma and myometrial smooth muscle cells. J Clin Endocrinol Metab. 2004;89(11):5549–5557.
47.
ChircoRLiuXWJungKKKimHR. Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev. 2006;25(1):99–113.
48.
LimperAHRomanJ. Fibronectin. A versatile matrix protein with roles in thoracic development, repair and infection. Chest. 1992, 101(6):1663–1673.
49.
GelseKPoschlEAignerT. Collagens--structure, function, and biosynthesis. Adv Drug Deliv Rev. 2003;55(12):1531–1546.
50.
ByersPH. Collagens: building blocks at the end of the development line. Clin Genet. 2000;58(4):270–279.
51.
PolgarAFalusAKooE. Elevated levels of synovial fluid antibodies reactive with the small proteoglycans biglycan and decorin in patients with rheumatoid arthritis or other joint diseases. Rheumatology (Oxford). 2003;42(4):522–527.
52.
OharaN. A putative role of versican in uterine leiomyomas. Clin Exp Obstet Gynecol. 2009;36(2):74–75.
53.
NorianJMMalikMParkerCYJosephDLeppertPCSegarsJHCatherinoWH. Transforming growth factor beta3 regulates the versican variants in the extracellular matrix-rich uterine leiomyomas. Reprod Sci. 2009;16(12):1153–1164.
54.
MujumdarVSTyagiSC. Temporal regulation of extracellular matrix components in transition from compensatory hypertrophy to decompensatory heart failure. J Hypertens. 1999;17(2):261–270.
55.
SternlichtMDWerbZ. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001;17:463–516.
56.
BogusiewiczMStryjecka-ZimmerMPostawskiKJakimiukAJRechbergerT. Activity of matrix metalloproteinase-2 and -9 and contents of their tissue inhibitors in uterine leiomyoma and corresponding myometrium. Gynecol Endocrinol. 2007;23(9):541–546.
57.
RahmanAHersheySAhmedSNibbelinkKSimpsonRU. Heart extracellular matrix gene expression profile in the vitamin D receptor knockout mice. J Steroid Biochem Mol Biol. 2007;103(3-5):416–419.
58.
HalderSKOsteenKGAl-HendyA. Vitamin D3 inhibits expression and activities of matrix metalloproteinase-2 and -9 in human uterine fibroid cells. Hum Reprod. 2013;28(9):2407–2416.
59.
NagaseH: Cell surface activation of progelatinase A (proMMP-2) and cell migration. Cell Res. 1998;8(3):179–186.
60.
WuJGarami MChengT, Gardner DG. 1,25(OH)2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. J Clin Invest. 1996;97(7):1577–1588.
61.
ZanelloSBCollinsEDMarinissenMJNormanAWBolandRL. Vitamin D receptor expression in chicken muscle tissue and cultured myoblasts. Horm Metab Res. 1997;29(5):231–236.
62.
MauskopfJFlynnMThiedaPSpaldingJDuchaneJ. The economic impact of uterine fibroids in the United States: a summary of published estimates. J Womens Health (Larchmt). 2005;14(8):692–703.
63.
HalderSKGoodwinJS, Al-Hendy A. 1,25-Dihydroxyvitamin D3 reduces TGF-beta3-induced fibrosis-related gene expression in human uterine leiomyoma cells. J Clin Endocrinol Metab. 2011;96(4):E754–E762.
64.
FlanaganJNZhengSChiangKC. Evaluation of 19-nor-2alpha-(3-hydroxypropyl)-1alpha,25-dihydroxyvitamin D3 as a therapeutic agent for androgen-dependent prostate cancer. Anticancer Res. 2009;29(9):3547–3553.
